ホーム>>Signaling Pathways>> Vitamin D Related>> VD/VDR>>Eldecalcitol

Eldecalcitol

カタログ番号GC35971

エルデカルシトール (ED-71) は、経口活性ビタミン D3 類似体であり、骨吸収を阻害し、骨ミネラル密度を増加させます。

Products are for research use only. Not for human use. We do not sell to patients.

Eldecalcitol 化学構造

Cas No.: 104121-92-8

サイズ 価格 在庫数 個数
1mg
$144.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Eldecalcitol (ED-71) is an analog of 1,25-dihydroxyvitamin D3 that improves bone mineral density. IC50 value:Target: Vd analogEldecalcitol (ED-71) is more efficacious than alfacalcidol in preventing vertebral and wrist fractures in osteoporotic patients with vitamin D sufficiency, with a safety profile similar to alfacalcidol.

[1]. Matsumoto T.Osteoporosis Treatment by a New Active Vitamin D3 Compound, Eldecalcitol, in Japan.Curr Osteoporos Rep. 2012 Aug 24. [2]. Shiraki M, et al. Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels.Curr Med Res Opin. 2012 Aug 23. [3]. Matsumoto T, Endo I.Eldecalcitol for the treatment of osteoporosis.Drugs Today (Barc). 2012 Mar;48(3):189-96. [4]. Sakai S, et al.Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength.Bone. 2012 May;50(5):1054-63. Epub 2012 Feb 17. [5]. Sanford M, McCormack PL.Spotlight on eldecalcitol in osteoporosis.Drugs Aging. 2012 Jan 1;29(1):69-71.

レビュー

Review for Eldecalcitol

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Eldecalcitol

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.